MacroGenics: Business Model, SWOT Analysis, and Competitors 2026

MacroGenics, Inc. stands as a leading company in Healthcare. Generating $127.63 million in annual revenue (growing -34.2% year-over-year) and carrying a market capitalization of $135.37 million, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, MacroGenics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines MacroGenics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating MacroGenics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define MacroGenics, Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How MacroGenics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering MacroGenics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who MacroGenics, Inc.'s main competitors are and how the company compares on key financial metrics
4. MacroGenics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. MacroGenics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $127.63 million annual revenue (TTM), +-34.2% YoY
• Market Cap: $135.37 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin -43.8%, operating margin 25.6%, net margin -59.5%
• Free Cash Flow: $-124.60 million
• Return on Equity: -81.1% — reflects current investment phase
• Employees: 341 worldwide

Who Owns MacroGenics, Inc.?

MacroGenics, Inc. is publicly traded on the NMS under the ticker symbol MGNX. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of MacroGenics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

MacroGenics, Inc. has approximately 0.06 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $2.14 per share as of early 2026.

MacroGenics, Inc.'s Mission Statement

MacroGenics, Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — MacroGenics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For MacroGenics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, MacroGenics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does MacroGenics, Inc. Make Money?

As of 2026, MacroGenics, Inc. generates $127.63 million in annual revenue (growing -34.2% year-over-year), with a -43.8% gross margin and 25.6% operating margin. Market capitalization stands at $135.37 million. Here is how the company generates its revenue:

Overview

Macrogenics operates primarily in the biopharmaceutical sector, focusing on the development of monoclonal antibodies for oncology and other therapeutic areas. The company employs a multi-faceted business model that combines research and development (R&D), strategic partnerships, and licensing agreements to drive its growth.

Revenue Streams

1. Product Sales: The primary revenue source for Macrogenics comes from the commercialization of its therapeutic products. This includes both direct sales and royalties from collaborations with larger pharmaceutical companies.

2. Partnerships and Collaborations: Macrogenics actively engages in partnerships with other biopharmaceutical companies. These collaborations often involve shared R&D costs, which can significantly reduce financial risk while providing access to additional resources and expertise.

3. Licensing Agreements: The company frequently enters into licensing agreements that allow other organizations to develop and market its therapeutic candidates. This not only generates upfront payments but also provides ongoing royalties based on sales.

4. Grants and Funding: Macrogenics may also benefit from government grants and funding for research initiatives, particularly in areas aligned with public health needs.

Strategic Focus

Macrogenics places a strong emphasis on innovation, particularly in the areas of:

• Targeted Oncology Treatments: The company is focused on developing therapies that target specific cancer types, which can lead to better patient outcomes and fewer side effects compared to traditional chemotherapy.

• Immunotherapy: Macrogenics is dedicated to advancing immunotherapeutic approaches, harnessing the body’s immune system to fight cancer more effectively.

• Pipeline Development: The company has a robust pipeline of drug candidates at various stages of clinical development, reflecting a commitment to long-term growth and sustainability.

Challenges

While the business model appears promising, Macrogenics faces challenges typical of the biotech industry, including high R&D costs, lengthy regulatory approval processes, and the inherent risks associated with drug development.

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review MacroGenics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

MacroGenics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how MacroGenics, Inc. creates, delivers, and captures value.

Key Partners: MacroGenics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: MacroGenics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: MacroGenics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (341 employees), proprietary technology, and financial resources ($146.40M in cash).

Value Propositions: MacroGenics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: MacroGenics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: MacroGenics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: MacroGenics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: MacroGenics, Inc.'s major costs include cost of goods sold (143.8% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 74.4% of revenue.

Revenue Streams: MacroGenics, Inc. generates revenue through its core product and service offerings.

MacroGenics, Inc. Competitors

MacroGenics, Inc.'s main competitors include Macrogenics addressing its. The company operates in the Biotechnology segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

MacroGenics, Inc.'s competitive position in Biotechnology is defined by its $135.37M market capitalization and -43.8% gross margins. Key competitive advantages include brand recognition and operational scale in the Biotechnology market.

MacroGenics, Inc. SWOT Analysis

A SWOT analysis examines MacroGenics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Established Market Position: MacroGenics, Inc. holds an established position in the Biotechnology sector, with a track record of serving customers and generating value across its core business activities.
• Industry Expertise: The company's deep expertise in Biotechnology — developed over years of operation — provides meaningful barriers to entry and customer relationship advantages that newer competitors must overcome.

Weaknesses

• Leverage Risk: MacroGenics, Inc.'s debt-to-equity ratio of 55.2 indicates meaningful financial leverage. Total debt stands at $37.01M against $146.40M in cash and equivalents.
• Revenue Decline: Year-over-year revenue declined 34.2%, raising questions about demand for MacroGenics, Inc.'s core offerings and requiring management to articulate a credible recovery path.

Opportunities

• Total Addressable Market: MacroGenics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for MacroGenics, Inc.'s products and services.
• Strategic Acquisitions: With $146.40M in cash and strong free cash flow generation, MacroGenics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. MacroGenics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on MacroGenics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

MacroGenics, Inc. enters 2026 as a leading company in Healthcare, backed by $127.63 million in annual revenue and a -59.5% net profit margin. The company's -43.8% gross margins and $-124.60 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in MacroGenics, Inc.'s core markets.

For investors and analysts, MacroGenics, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – MacroGenics, SEC EDGAR – MacroGenics Filings, and MacroGenics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What is Macrogenics Inc.?

MacroGenics, Inc. generated $127.63 million in annual revenue with a -59.5% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult MacroGenics, Inc.'s investor relations page.

2. What is the business model of Macrogenics?

MacroGenics, Inc. generates $127.63 million in annual revenue (TTM) with a -43.8% gross margin, growing -34.2% year-over-year. The company's revenue model is described in detail in the business model section above.

3. What are the key strengths of Macrogenics?

MacroGenics, Inc.'s core strengths include: MacroGenics, Inc. holds an established position in the Biotechnology sector, with a track record of serving customers and generating value across its core business activities. The company's deep expertise in Biotechnology — developed over years of operation — provides meaningful barriers to entry and customer relationship advantages that newer competitors must overcome. These advantages contribute to the company's durable competitive position in the Biotechnology sector.

4. Who are Macrogenics' main competitors?

MacroGenics, Inc. competes in the Biotechnology segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Biotechnology center on product differentiation, pricing strategy, and distribution scale.

5. What opportunities does Macrogenics have in the market?

MacroGenics, Inc.'s key growth opportunities include: MacroGenics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for MacroGe With $146.40M in cash and strong free cash flow generation, MacroGenics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

6. What threats does Macrogenics face?

MacroGenics, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. MacroGenics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recessio Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on MacroGenics, Inc.'s Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

7. How is Macrogenics addressing its weaknesses?

MacroGenics, Inc.'s primary weaknesses include: MacroGenics, Inc.'s debt-to-equity ratio of 55.2 indicates meaningful financial leverage. Total debt stands at $37.01M against $146.40M in cash and equivalents. Year-over-year revenue declined 34.2%, raising questions about demand for MacroGenics, Inc.'s core offerings and requiring management to articulate a credible recovery path. These factors represent risks that investors and analysts should weigh against the company's competitive strengths.